7th March 2017
We are delighted to announce that the first UK clinical trial for people with Rett Syndrome, launched today, will be conducted by Dr Paramala Santosh and team at the Clinical Research Facility at King’s College Hospital, London.
The 24-week study is a double-blind placebo-controlled trial of Sarizotan, a compound specifically being tested to reduce breathing irregularities in people with Rett Syndrome.
This study is a unique and collaborative effort between the academic department at King's College London, clinical service in the South London & Maudsley NHS Foundation Trust, and the Clinical Research Facility at King's College Hospital. The study is sponsored by Newron Pharmaceuticals.
This will be the first time that the UK will be contributing to data which may be used for licensing of a medication in Rett Syndrome.
Patients who are 13 years or older and who have a body weight of 25kg or over may be eligible.
If you would like to express interest in your daughter or son participating in this trial and you have not yet registered them on the Reverse Rett Patient Registry, please contact firstname.lastname@example.org in the first instance.
Please read the full press release below.